Immunotherapy is very novel in the anticancer treatment modalities.  It is part of multiple trials performed at City of Hope.  Side effects like immunotherapy hepatitis is very common and management is evolving. Dr. Kahn is the director at USC for liver transplantation and has great expertise in using specialized immunosuppressive medications (like tacrolimus, mycophenolate) used in liver transplant recipients. These same medications are considered potential treatment in refractory cases of immunotherapy related hepatitis as per some studies. Therefore we need guidance and information regarding current data regarding these medications.  

Being that immunotherapy is very novel in treatment of multiple cancers, there is limited information about management of side effects. Immunotherapy-related hepatitis occurs in up to 1% to 7% of patients during monotherapy and up to 13% to 30 % cases treated with combination therapy with immunotherapy. Current treatment involves treatment with corticosteroids, however, there are many patients who have steroid refractory hepatitis and treatment for these patients is limited and involves use of other immunosuppressive medications (like tacrolimus, mycophenolate) and there is limited data and guidelines to address this question.  This activity will help providers keep up-to-date with current practice and provide education about new treatment strategies and latest research in this area.